Trial · NCT02748135
A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma
NCT02748135, Phase 1, Completed, Oncurious NV
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma. Trials, record NCT02748135. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02748135
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma
- NCT number
- NCT02748135
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 18 participants, actual
- Lead sponsor
- Oncurious NV
- Conditions
- Relapsed or Refractory Medulloblastoma (MB), Neuroblastoma (NB), Ewing Sarcoma (ES) and Alveolar Rhabdomyosarcoma (ARMS)
- Interventions
- TB-403 20mg/kg, TB-403 50mg/kg, TB-403 100mg/kg, TB-403 175mg/kg
- First posted
- 2016-04-22
- Last updated
- 2021-01-13
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The primary safety endpoint will be the determination of the maximum tolerated dose (MTD) / study maximum dose (SMD) based on the occurrence of dose-limiting toxicities (DLTs) during the 28-day DLT assessment period. | Day28 | |
| Secondary | TB-403 total exposure (AUC∞) after single ascending dose | Day 1, day 4, day 8, day 15, day 29, day 60, day 90, day 165 and day 195. | |
| Secondary | TB-403 Dose/CL after single ascending dose | Day 1, day 4, day 8, day 15, day 29, day 60, day 90, day 165 and day 195. | |
| Secondary | TB-403 Volume of the central compartment (Vc) after single ascending dose | Day 1, day 4, day 8, day 15, day 29, day 60, day 90, day 165 and day 195. | |
| Secondary | TB-403 Volume of distribution at steady-state (Vss) after single ascending dose | Day 1, day 4, day 8, day 15, day 29, day 60, day 90, day 165 and day 195. | |
| Secondary | TB-403 terminal half-life (t½,z) after single ascending dose | Day 1, day 4, day 8, day 15, day 29, day 60, day 90, day 165 and day 195. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02748135
GET https://conductscience.org/api/trials/v1/NCT02748135/registered